Abstract: The invention provides assays and methods for characterization of specific extracellular vesicle (EV) populations, and to the preparation of improved EV compositions for therapy and diagnosis. Specifically, the invention in embodiments thereof provides methods and kits for analyzing blood-derived samples, as well as to the production and use of tissue-derived circulating EV populations characterized by unexpectedly small dimensions and advantageous properties.

Abstract: The present invention provides improved and minimally invasive biomarker-based diagnostics for synucleinopathies (e.g., Parkinson's disease (PD)). The invention further provides assays and methods for analysis of biological samples, for the evaluation and determination of characteristics pertaining to pathological processes associated with ?-synuclein, and to methods for determining the suitability of analytical agents for diagnosis of synucleinopathies. More specifically, the invention in embodiments thereof provides improved methods comprising specific detection and quantification of ?-synuclein-based biomarkers from low volumes of biological samples.

Abstract: The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.

Abstract: The present invention relates to minimally invasive, biomarker-based diagnostics for neurodegenerative diseases, and to compositions and methods for isolating and analyzing specific populations of extracellular vesicles (EV). In particular, embodiments of the invention relate to methods and systems for isolating, identifying or capturing neuron-derived EV, for analyzing biological samples, and for diagnosing, assessing and predicting the development of neurological and neurodegenerative conditions.

Abstract: The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.